Pharmanutra
PharmaNutra SpA is an Italian pharmaceutical and nutraceutical company specializing in iron-based nutritional supplements and medical devices. The company formulates and manufactures Sucrosomial Iron technology supplements under the SiderAL brand alongside topical joint pain products under the Cetilar brand. Principal revenues are generated through product sales of nutritional supplements and medical devices via pharmacy chains, healthcare distributors, and international licensing partners. Core end markets serve iron-deficiency patients, orthopedic individuals, sports medicine users, and retail pharmacy consumers in Italy and export markets. PharmaNutra holds a market-leading position in Italy for oral iron supplements and Sucrosomial delivery technologies. The company is headquartered in Pisa, Italy, and its ordinary shares trade on the Euronext STAR Milan exchange.
5 of the funds FundTelligence covers report a position in Pharmanutra.
- Legal name
- Pharmanutra SpA
- Sector
- Health Care
- Country
- Italy
- Funds holding it
- 5
Funds holding Pharmanutra
- Danske Invest Europe Small Cap — Danske Invest · 3.3 % (largest positions only, October 2026)
- Holberg Global — Holberg · 1.49 % (full portfolio disclosed, October 2026)
- JPM Europe Small Cap Fund — JPM · 0.38 % (full portfolio disclosed, June 2026)
- JPM Europe Sustainable Small Cap Equity Fund — JPM · 0.2 % (full portfolio disclosed, June 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.0 % (partially disclosed portfolio, June 2026)